ERA PerMed JTC2021 Midterm Symposium – Advancing Clinical Support Tools for Personalised Medicine
The symposium brought together researchers, clinicians, funders and patient representatives to discuss the progress and outcomes of the ERA PerMed projects and featured presentations from 21 interdisciplinary consortia funded under the JTC2021 call, which focuses on the development of clinical support tools to facilitate the implementation of personalised medicine. The participants explored cutting-edge research in disease fields such as oncology, neurology, cardiovascular diseases and rare diseases, showcasing innovations in AI-driven diagnostics, machine learning models, biomarker discovery, and precision treatment approaches.
The symposium also included a workshop on Responsible Research and Innovation (RRI). This session provided an interactive platform for participants to reflect on their current research practices, focusing on transparency and clinical validity. The workshop began with a presentation outlining key challenges in the field and strategies to ensure robust knowledge generation. Early-career researchers engaged in discussions on how to enhance transparency in data, methods and computations within their research, while principal investigators examined the evaluation of clinical validity in their projects. The workshop provided practical insights on integrating RRI principles into research, reinforcing the importance of ethical and responsible research practices.
Additionally, a discussion on patient engagement in personalised medicine research highlighted the importance of involving patients at all stages of research. Patient representatives shared concrete strategies for fostering meaningful collaboration and ensuring that research outcomes align with patient needs. Scientific experts and patient representatives were also present, providing feedback on the progress and outcomes of the JTC2021-funded projects. Their insights will support both the funders in evaluating the progress and outcomes of the projects and the consortia in refining their research approaches
The PerSAIDs Project Coordinator was invited as a speaker during the session «Integration of multi-omics for personalized approaches».
From EP PerMed Conference official Website page: https://www.eppermed.eu/berlin-2025
“Isabella Ceccherini (IRCCS Istituto Giannina Gaslini, Italy) coordinates the ‘PERsonalised medicine for SAIDs (PerSAIDs)‘ project, funded under ERA PerMed JTC2021. In their project, Isabella and her colleagues focus on rare and heterogeneous systemic auto-inflammatory diseases (SAIDs). At our conference, Isabella highlighted the need for additional datasets to validate their results for translation into clinical practice. Transnational collaboration through the ERA PerMed funding scheme has enabled the consortium to expand it’s scope and increase the number of patients and data sets collected.”
Video interview at this link: https://www.youtube.com/watch?v=4UgrTsyll0I&t=2
The poster sessions provided a platform for young researchers from the funded consortia to present their work and engage in discussions with their peers and senior scientists. An Early Researcher Carrer collaborating within our project was invited to present a poster explaining the aims of the project.
By bringing together various leading and young researchers, clinical experts, patient representatives, and funding agencies, the symposium fostered international collaboration, encouraged multidisciplinary dialogue, and reinforced EP PerMed’s role in driving forward personalised healthcare solutions through funding excellent personalised medicine research.
link: https://www.eppermed.eu/news-events/news/era-permed-jtc2021-midterm-symposium-advancing-clinical-support-tools-for-personalised-medicine/
awesome
Great summary of the EP PerMed Conference! It’s very encouraging to see such a strong focus on integrating multi-omics data, AI-driven diagnostics, and patient engagement to advance personalized medicine for complex conditions like SAIDs.
The emphasis on validating results with additional datasets for clinical translation is a crucial point. This makes me wonder about the practical aspects of bringing these advanced diagnostics to patients. For instance, in the realm of personalized treatment approaches, how do researchers and clinicians account for and manage potential adverse reactions or side effects from novel therapeutic combinations that might be recommended by these new clinical support tools? I was reading about patient safety profiles for various treatments on a resource like https://pillintrip.com/medicine/permed, and it sparked this question about the balance between personalized efficacy and standardized safety protocols within the frameworks being discussed.
Is there a specific protocol within the PerSAIDs project or the broader ERA PerMed initiative for monitoring and addressing these aspects in real-world clinical practice?